$FOMI
FORMATION MINERALS, INC.

2024 Q1 Form 10-Q Financial Statement

#000121390024025574 Filed on March 25, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $828.4K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $0.00
YoY Change -100.0%
Operating Profit -$828.4K
YoY Change 433.1%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.348M
YoY Change 756.04%
Income Tax
% Of Pretax Income
Net Earnings -$1.348M
YoY Change 778.59%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$0.02
COMMON SHARES
Basic Shares Outstanding 56.35M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00
YoY Change
Cash & Equivalents $26.96K
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables $0.00
Total Short-Term Assets $39.65K
YoY Change -90.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $39.65K
Total Long-Term Assets $0.00 $0.00
Total Assets $39.65K
YoY Change -90.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $291.3K
YoY Change
Accrued Expenses $43.50K $52.00K
YoY Change -33.48% -20.87%
Deferred Revenue
YoY Change
Short-Term Debt $100.2K $82.82K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $617.9K $1.101M
YoY Change -31.95% 24.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $617.9K $1.101M
Total Long-Term Liabilities $0.00
Total Liabilities $617.9K $1.101M
YoY Change -31.95% 21.97%
SHAREHOLDERS EQUITY
Retained Earnings -$3.483M -$6.027M
YoY Change -39.92% 35.95%
Common Stock $1.211M $1.073M
YoY Change 19.11% 74.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$617.9K -$1.284M
YoY Change
Total Liabilities & Shareholders Equity $39.65K
YoY Change -90.98%

Cashflow Statement

Concept 2024 Q1 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.348M
YoY Change 778.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$12.82K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$26.79K
YoY Change
Cash From Investing Activities -$26.79K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.89K
YoY Change
NET CHANGE
Cash From Operating Activities -12.82K
Cash From Investing Activities -26.79K
Cash From Financing Activities 29.89K
Net Change In Cash -9.720K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$12.82K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-01-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
SENSASURE TECHNOLOGIES INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity File Number
EntityFileNumber
001-41209
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2406468
dei Entity Address Address Line1
EntityAddressAddressLine1
4730 S. Fort Apache Rd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89147
dei City Area Code
CityAreaCode
(347)
dei Local Phone Number
LocalPhoneNumber
325-4677
dei Security12b Title
Security12bTitle
None
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56349183 shares
CY2023Q2 us-gaap Cash
Cash
26786 usd
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
172 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
12688 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
39646 usd
CY2023Q2 us-gaap Assets
Assets
39646 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
63500 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
105868 usd
CY2024Q1 sesu Demand Loan Current
DemandLoanCurrent
100172 usd
CY2023Q2 sesu Demand Loan Current
DemandLoanCurrent
113375 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
617853 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1101239 usd
CY2024Q1 us-gaap Liabilities
Liabilities
617853 usd
CY2023Q2 us-gaap Liabilities
Liabilities
1101239 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56349183 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56349183 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
563492 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
425431 usd
CY2024Q1 sesu Shares To Be Issue
SharesToBeIssue
804000 shares
CY2023Q2 sesu Shares To Be Issue
SharesToBeIssue
804000 shares
CY2024Q1 sesu Shares To Be Issued Value
SharesToBeIssuedValue
15755 usd
CY2023Q2 sesu Shares To Be Issued Value
SharesToBeIssuedValue
15755 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2286039 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4533073 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-231505 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3483139 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6027209 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-617853 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1284455 usd
CY2023Q2 us-gaap Noncontrolling Interest In Variable Interest Entity
NoncontrollingInterestInVariableInterestEntity
42061 usd
CY2023Q2 sesu Development Reserve
DevelopmentReserve
180801 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-617853 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1061593 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39646 usd
us-gaap Revenues
Revenues
1146 usd
us-gaap Revenues
Revenues
4414 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
828374 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
100638 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1124726 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
414547 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54750 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10145 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74171 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-828374 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-155388 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1134871 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-488718 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
2059 usd
us-gaap Interest Expense
InterestExpense
4009 usd
us-gaap Interest Expense
InterestExpense
6191 usd
CY2024Q1 us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
-519442 usd
us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
-519442 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1347816 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-157447 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1657176 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-490495 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-1347816 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-157447 usd
us-gaap Profit Loss
ProfitLoss
-1657176 usd
us-gaap Profit Loss
ProfitLoss
-490495 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4041 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1801 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9838 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1347816 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-153406 usd
us-gaap Net Income Loss
NetIncomeLoss
-1655375 usd
us-gaap Net Income Loss
NetIncomeLoss
-480657 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.024
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.002
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.029
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.005
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56349183 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81764161 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56349183 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97736842 shares
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-1347816 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-157447 usd
us-gaap Profit Loss
ProfitLoss
-1657176 usd
us-gaap Profit Loss
ProfitLoss
-490495 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-37760 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
66783 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
35597 usd
sesu Deconsolidation Of Subsidiary
DeconsolidationOfSubsidiary
66783 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1347816 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-195207 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1657176 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-454898 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1347816 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-153406 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1655375 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-480657 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-35317 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
61374 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
33295 usd
sesu Deconsolidation Of Subsidiary Deficit
DeconsolidationOfSubsidiaryDeficit
61374 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
4041 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
1801 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
9838 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2443 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
5409 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2302 usd
sesu Deconsolidation Of Subsidiary Noncontrollin Interest
DeconsolidationOfSubsidiaryNoncontrollinInterest
5409 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1347816 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-195207 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1657176 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-454898 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1150170 usd
CY2024Q1 sesu Stock Issued During Period Value Amortization Of Vested Shares
StockIssuedDuringPeriodValueAmortizationOfVestedShares
812426 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-1347816 usd
CY2024Q1 us-gaap Noncontrolling Interest Decrease From Deconsolidation
NoncontrollingInterestDecreaseFromDeconsolidation
1067707 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-617853 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-691179 usd
CY2023Q1 sesu Stock Issued During Period Value Amortization Of Vested Shares
StockIssuedDuringPeriodValueAmortizationOfVestedShares
7288 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
39760 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-157447 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-37760 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-839338 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1061593 usd
sesu Stock Issued During Period Value Amortization Of Vested Shares
StockIssuedDuringPeriodValueAmortizationOfVestedShares
966426 usd
us-gaap Profit Loss
ProfitLoss
-1657176 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
66783 usd
us-gaap Noncontrolling Interest Decrease From Deconsolidation
NoncontrollingInterestDecreaseFromDeconsolidation
1067707 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-617853 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-463205 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
45 usd
sesu Stock Issued During Period Value Amortization Of Vested Shares
StockIssuedDuringPeriodValueAmortizationOfVestedShares
36440 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
42280 usd
us-gaap Profit Loss
ProfitLoss
-490495 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
35597 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-839338 usd
us-gaap Profit Loss
ProfitLoss
-1657176 usd
us-gaap Profit Loss
ProfitLoss
-490495 usd
sesu Amortization Of Vested Shares
AmortizationOfVestedShares
966426 usd
sesu Amortization Of Vested Shares
AmortizationOfVestedShares
36440 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
42280 usd
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
-519442 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-465 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
11446 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-9545 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-43423 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
59389 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
65073 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-28673 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120999 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-430244 usd
us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
26786 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26786 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
45 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
29893 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
39979 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
70279 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
100172 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40024 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20655 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7670 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26958 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-382550 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26958 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
437177 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54627 usd
us-gaap Nature Of Operations
NatureOfOperations
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION OF BUSINESS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SensaSure Technologies, Inc. (“SensaSure”, “Company”, “we”, “us” or “our”) was incorporated on September 8, 2020 under the laws of the State of Nevada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sensabues AB (“Sensabues”) was incorporated in the Kingdom of Sweden in November 2009. Until November 1, 2023, Sensabues owned the core intellectual properties for the design of sample collection devices and the methodologies to collect, extract and detect the non-volatile substances presented within aerosols in exhaled breath. These aerosols, which originate from the lungs and blood, are captured using electret-based filter technologies.  This non-invasive breath-based biological sample collection and testing methodology is called ExaBreath (“EB”) technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2020, the Company completed a reverse recapitalization via a share exchange agreement with Sensabues and the shareholders who owned 270,339 common shares that represented 72.82% of the total issued and outstanding common shares in Sensabues. Under the share exchange agreement, the shareholders of Sensabues, agreed to exchange their shares of Sensabues for common shares of SensaSure at an exchange ratio of approximate 1:49.99. Pursuant to the share exchange transactions (see share exchange agreement noted above), SensaSure issued a total of 13,515,183 common shares and the then- shareholders of Sensabues hold their ownership of Sensabues through SensaSure (Note 8 (b)). Upon completion of the share exchange transaction, SensaSure became the controlling shareholder that owned 74.82% the total issued and outstanding common shares in Sensabues and parent company of Sensabues. No goodwill or other intangible assets were recorded during the reverse capitalization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During April 2021, the Company increased its ownership interest in Sensabues pursuant to private placements completed by Sensabues where 277,296 common shares and 93,032 common shares were issued to the Company and noncontrolling interests respectively. (Note 8 (b)).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended January 31, 2023, the Company increased its ownership interest in Sensabues pursuant to private placements completed by Sensabues where 2,200,000 common shares and 440 common shares were issued to the Company and noncontrolling interests respectively. (Note 8 (b)).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 31, 2023, the Company owned 93.53% (93.53% - April 30, 2023) of the total issued and outstanding common shares in Sensabues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended January 31, 2024, the Company began winding-up the business of Sensabues to reduce operating expenses associated with maintaining the exhale breath technology patents. Since then, management of the Company has been in the process of establishing a new business segment to develop energy related businesses which led to the entry into that certain agreement and plan of merger with Verde Bio Holdings, Inc., a Nevada corporation (“Verde”), and Formation Minerals Inc., a Nevada corporation and our wholly-owned subsidiary (“Merger Sub”), as of December 11, 2023, as amended as of February 8, 2024 (the “Merger Agreement”), providing for the merger of Merger Sub with and into Verde, with Verde continuing as the surviving entity (the “Merger”). Subject to the satisfaction or waiver of the closing condition, we expect to close the Merger in the second quarter of calendar year 2024. As of February 26, 2024, the Sensabues business is no longer under the control of the Company and will cease to exist upon the completion of bankruptcy procedures. Following the Merger, we intend to focus on the acquisition and management of high quality, cash flowing oil and gas minerals and royalties under Verde’s current business plan.</p>
CY2020Q4 sesu Common Shares Exchange Ratio
CommonSharesExchangeRatio
1:49.99
CY2021Q2 sesu Common Shares Noncontrolling Interests
CommonSharesNoncontrollingInterests
93032 shares
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3483139 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6027209 usd
CY2024Q1 sesu Working Capital Deficiency
WorkingCapitalDeficiency
617853 usd
CY2023Q2 sesu Working Capital Deficiency
WorkingCapitalDeficiency
1061593 usd
CY2023Q2 sesu Working Capital Loans
WorkingCapitalLoans
39979 usd
CY2024Q1 sesu Working Capital Loans
WorkingCapitalLoans
100172 usd
CY2021Q1 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
333744 usd
us-gaap Use Of Estimates
UseOfEstimates
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical management judgment and use of estimates</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals, stock options, principles of consolidation and reverse recapitalization and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.</p>
CY2024Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
20000 usd
CY2023Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
53868 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43500 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
52000 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
63500 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
105868 usd
us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.50 pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
0.01
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021 sesu Proceeds From Private Placement
ProceedsFromPrivatePlacement
793000 usd
CY2021 sesu Proceed From Issuance Of Common Stock
ProceedFromIssuanceOfCommonStock
12200000 shares
CY2021 sesu Issued Of Common Shares
IssuedOfCommonShares
11780000 shares
CY2024Q1 sesu Proceeds Received In Common Stock
ProceedsReceivedInCommonStock
117800 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
647900 usd
CY2021Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
27300 usd
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
420000 shares
CY2022 sesu Subscription Proceeds Received
SubscriptionProceedsReceived
420000 shares
CY2023Q2 sesu Unsecured Demand Loan Non Controlling Interests
UnsecuredDemandLoanNonControllingInterests
28550 usd
CY2024Q1 sesu Unsecured Demand Loan Non Controlling Interests
UnsecuredDemandLoanNonControllingInterests
293000 sek
us-gaap Interest Expense Debt
InterestExpenseDebt
2719 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
4109 usd
CY2024Q1 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
100172 usd
CY2023Q2 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
39979 usd
CY2023Q2 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
53591 usd
CY2023Q2 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
550000 sek
CY2024Q1 us-gaap Percentage Of Interest Bearing Domestic Deposits To Deposits
PercentageOfInterestBearingDomesticDepositsToDeposits
0.02 pure
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10145 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74171 usd
CY2021Q1 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
333744 usd
CY2021Q1 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
798280 sek
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56349183 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56349183 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56349183 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56349183 shares
sesu Share Based Compensation Fair Value
ShareBasedCompensationFairValue
3780 usd
CY2023 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
750000 shares
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
35761 usd
CY2023Q1 us-gaap Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares
StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
8800000 shares
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1650000 shares
CY2023 sesu Share Based Compensation Fair Value
ShareBasedCompensationFairValue
115500 usd
CY2023 us-gaap Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued
DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
16500 usd
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
550000 shares
CY2023Q1 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
5500 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
4950000 shares
CY2024Q1 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
49500 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
250326 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
500500 usd
CY2023 sesu Unvested Shares
UnvestedShares
7150000 shares
CY2023Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
59804 usd
CY2022Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
108102 usd
CY2023Q4 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
10000000 usd
CY2023Q4 us-gaap Investment Company Market Value Per Share
InvestmentCompanyMarketValuePerShare
0.75
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
CY2024Q1 sesu Subscription Receivable
SubscriptionReceivable
usd
CY2023Q2 sesu Subscription Receivable
SubscriptionReceivable
usd
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
usd
CY2024Q1 us-gaap Assets
Assets
usd
CY2024Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
usd
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
usd
CY2024Q1 us-gaap Noncontrolling Interest In Variable Interest Entity
NoncontrollingInterestInVariableInterestEntity
usd
CY2024Q1 sesu Development Reserve
DevelopmentReserve
usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
usd
CY2024Q1 us-gaap Revenues
Revenues
usd
CY2023Q1 us-gaap Revenues
Revenues
usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
usd
CY2023Q1 us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.002
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.005
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.024
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.029
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
CY2024Q1 sesu Deconsolidation Of Subsidiary
DeconsolidationOfSubsidiary
usd
CY2023Q1 sesu Deconsolidation Of Subsidiary
DeconsolidationOfSubsidiary
usd
sesu Deconsolidation Of Subsidiary
DeconsolidationOfSubsidiary
usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
usd
CY2024Q1 sesu Deconsolidation Of Subsidiary Deficit
DeconsolidationOfSubsidiaryDeficit
usd
sesu Deconsolidation Of Subsidiary Deficit
DeconsolidationOfSubsidiaryDeficit
usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
usd
CY2024Q1 sesu Deconsolidation Of Subsidiary Noncontrollin Interest
DeconsolidationOfSubsidiaryNoncontrollinInterest
usd
sesu Deconsolidation Of Subsidiary Noncontrollin Interest
DeconsolidationOfSubsidiaryNoncontrollinInterest
usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
usd
us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
usd
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
usd
us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q1 sesu Unsecured Demand Loan Non Controlling Interests
UnsecuredDemandLoanNonControllingInterests
usd
CY2024Q1 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
usd
CY2024Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
usd
CY2024Q1 us-gaap Other Long Term Debt
OtherLongTermDebt
usd
CY2023Q2 us-gaap Other Long Term Debt
OtherLongTermDebt
usd
sesu Unvested Shares Amount
UnvestedSharesAmount
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001885336
dei No Trading Symbol Flag
NoTradingSymbolFlag
true

Files In Submission

Name View Source Status
0001213900-24-025574-index-headers.html Edgar Link pending
0001213900-24-025574-index.html Edgar Link pending
0001213900-24-025574.txt Edgar Link pending
0001213900-24-025574-xbrl.zip Edgar Link pending
ea0202438-10q_sensasure.htm Edgar Link pending
ea020243801ex31-1_sensasure.htm Edgar Link pending
ea020243801ex32-1_sensasure.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ea0202438-10q_sensasure_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sesu-20240131.xsd Edgar Link pending
Show.js Edgar Link pending
sesu-20240131_def.xml Edgar Link unprocessable
sesu-20240131_lab.xml Edgar Link unprocessable
sesu-20240131_pre.xml Edgar Link unprocessable
sesu-20240131_cal.xml Edgar Link unprocessable